CST, 91942S, Dabrafenib (GSK2118436)

Product Usage Information
Dabrafenib (GSK2118436) is supplied as a lyophilized powder. For a 10 mM stock, reconstitute 5 mg of powder in 962 μl of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Storage
Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
Background
Dabrafenib (GSK2118436) is a selective and potent B-Raf inhibitor. The compound inhibits mutant B-Raf and B-Raf with IC values of 0.6 nM and 0.5 nM, respectively, and is less effective at inhibiting wild-type B-Raf and C-Raf (IC = 3.2 nM and 5.0 nM, respectively) (1). Dabrafenib (GSK2118436) has also been shown to inhibit cell proliferation and ERK signaling in melanoma cell lines carrying the B-Raf and B-Raf mutations as compared to wild-type B-Raf (2). The specificity of this compound makes it a useful reagent when studying metastatic melanoma with B-Raf mutations (3). This product has applications to SARS-CoV-2 research into the mechanisms of the Novel Coronavirus, which has caused the COVID-19 pandemic.
Alternate Names
Dabrafenib; GSK2118436; N-[3-[5-2-amino-4-pyrimidinyl-2-11-dimethylethyl-4-thiazolyl]-2-fluorophenyl]-26-difluoro- benzenesulfonamide